Market sequence and route assessment
We first clarify which markets should move first, what evidence can be reused, and where gaps must be closed.
LLINS Tech
Start medical device global market entry with a clear registration route map
LLINS Tech helps medical device and IVD manufacturers plan registration routes, structure technical evidence, diagnose review issues, and coordinate clinical, performance, and representative requirements across CE/MDR/IVDR, FDA, Canada, Australia, Southeast Asia, Turkey, and other priority markets.
Route Planning Snapshot
Master dossier and evidence system
Technical documentation, performance data, clinical evidence, and quality requirements are organized as one traceable structure.
Review response and maintenance rhythm
When review issues appear, we diagnose the root cause before shaping evidence, remediation, and representative maintenance.
2017
supporting medical device regulatory, registration, and market access programs
Route map + master dossier
planning market sequence, evidence gaps, and reusable documentation together
Review diagnosis
root-cause analysis and remediation planning for NB, FDA, and local review issues
Representative + maintenance
linking local representation, certificate maintenance, and post-market compliance
Who We Support
Different teams need different regulatory answers
We first identify the team’s stage and then decide whether the work should start with route planning, dossier structuring, review diagnosis, innovation pathway assessment, or representative maintenance.
Export and business leaders
Need market priority, registration investment, dossier reuse, and order timing to be considered together.
Established QARA teams
Need external second opinion, review issue diagnosis, NC close-out logic, and cross-document consistency checks.
IVD and innovation teams
Need early judgment on clinical, performance, software, AI, or new-technology evidence routes.
Foreign-invested and cross-border teams
Need China-based support, representative maintenance, workshops, and overseas coordination in one operating layer.
Regulatory Intelligence
RegDB
A regulatory, local representative, and licensing risk intelligence entry point for global markets, maintained with source traceability, verification status, and cautious boundaries.
Selected Clients
A snapshot of teams we have supported
These marks offer a quick view of the organizations and brands represented across past project work.
Core Services
Five productized services connected by one global market-entry track
Instead of splitting regulatory work into isolated tasks, LLINS Tech connects route planning, master dossier work, review diagnosis, innovation pathways, and representative maintenance in one delivery flow.
Global registration route map
Clarify market sequence, classification, evidence gaps, dossier reuse, and project priorities before execution starts.
CE/FDA and multi-market execution
Support CE/MDR/IVDR, FDA, Canada, Australia, Southeast Asia, Turkey, and related market-entry workstreams.
Second Opinion and review diagnosis
Diagnose NB/FDA open issues, remediation requests, evidence gaps, and cross-document impact before response drafting.
IVD clinical and innovation pathways
Assess feasibility and evidence routes for IVD, POCT, software, AI, and other innovation-driven device programs.
Representative and overseas compliance maintenance
Coordinate local representatives, importer/distributor responsibility, certificate maintenance, PMS, and vigilance expectations.
Market Coverage
Priority markets stay clear instead of becoming a long country list
Other countries or regions can be assessed project by project based on product type, evidence maturity, and representative resources.
EU CE / MDR / IVDR
Technical documentation, clinical and performance evidence, notified body questions, representative work, and maintenance requirements.
US FDA
510(k), De Novo, QMSR, US agent requirements, and review issue response planning.
Canada
Classification, license pathway, MDSAP linkage, and English dossier consistency.
Australia
TGA route assessment, existing CE/FDA evidence use, sponsor responsibility, and maintenance planning.
Southeast Asia
Route assessment, dossier adaptation, and local coordination for Singapore, Malaysia, Thailand, Vietnam, and Indonesia.
Turkey and other markets
Project-based feasibility review according to product category, evidence maturity, and representative availability.
Delivery Model
See the route clearly before accelerating the work
Speed matters in regulatory programs, but speed on the wrong route creates more waste. The delivery model is designed to clarify assumptions, evidence gaps, and service boundaries early.
Assess the current state
Review target markets, classification, existing evidence, review issues, testing gaps, and quality system maturity.
Design the market-entry route
Set market priorities, dossier reuse logic, representative needs, and realistic milestones for the program.
Organize documentation and support resources
Link technical files, testing work, clinical or performance evidence, and quality actions into one coordinated timeline.
Submit, maintain, and extend
Support submission, review responses, post-market obligations, representative coordination, and future market expansion.
Operating Footprint
China-based coordination with connections into Europe, the US, and overseas support resources
Public company information shows operating contacts in Shanghai and Hangzhou, together with links to representative resources in Europe and the US, plus overseas testing and clinical collaboration.
Office and contact points
- Shanghai Room 1115, Building A, Xuhui Vanke Center, No.55 Ding'an Road
- Hangzhou Room 1012, Tianheng Building, 1509 Binsheng Road, Binjiang District
- Overseas coordination Europe and US representative resources, plus overseas testing and clinical partners
Best fit engagements
- First-time entry into EU, US, Canada, Australia, Southeast Asia, or Turkey, with the route still undefined
- Existing technical documents are available, but cross-market mapping is inefficient
- Review issues, representative services, QMS work, and registration preparation need one coordinated operating layer
Contact
Choose the right entry point for the first discussion
A short first discussion usually clarifies the direction and key gaps. It does not replace formal regulator or notified body decisions.
Request route assessment
For teams that need to decide whether CE, FDA, Canada, Australia, or Southeast Asia should move first.
Submit a review issue for initial diagnosis
For projects with NB, FDA, or local authority comments that need root-cause and remediation planning.
Assess an innovation or IVD pathway
For IVD, POCT, software, AI, or new-technology products where evidence feasibility matters early.
Central inquiry desk
LLINS Tech
info@llins-tech.com +86 189 6648 5232 Include the product, target market, current issue, and timing context in your first note.Shanghai office
Regulatory project coordination
info@llins-tech.com Room 1115, Building A, Xuhui Vanke Center, No.55 Ding'an Road, Xuhui District, ShanghaiHangzhou office
Registration documentation and project support
info@llins-tech.com Room 1012, Tianheng Building, 1509 Binsheng Road, Binjiang District, Hangzhou, ZhejiangStart With Clarity